All News

Fracture.spine_.op_.jpg (keep)

Consensus on Managing Vertebral Fractures in Advanced CKD

EurekAlert!

A coalition of leading international experts have released the first comprehensive Consensus Statement on the Management of Vertebral Fractures in Chronic Kidney Disease (CKD) Stages G4–G5D.

Read Article
gout target T2T

Treat-to-Target in Gout and Cardiovascular Outcomes

Jack Cush, MD

A 5 year JAMA study shows that a treat-to-target (serum urate < 6 mg/dL) study finds that effective urate-lowering treatment (ULT) results in a significantly reduced cardiovascular risk in patients with gout. 

Read Article
RheumNow Podcast square

Emergencies, Independence & Hemorrhage (1.23.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and reports from the past two weeks on RheumNow.Com

Read Article
lung,cancer,blue,mass

BIOBADASER III Registry shows No Cancer Risk with b/tsDMARDs

Jack Cush, MD

A large, real-world cohort study of rheumatoid arthritis (RA) finds patients treated with biologic and targeted synthetic DMARDs (b/tsDMARDs) do not have an increased risk of cancer. 

Read Article
early.RA_.jpg

APPIPRA Study - Benefits of Early Treatment

EurekAlert!

Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with benefits also continuing well after treatment has stopped.

Read Article
APR MTX Cover

Methotrexate

Jack Cush, MD

In this session, Dr. Jack Cush reviews methotrexate.

Read Article
joint.pain_.hand_.PIP_.jpg

Are JAK Inhibitors Better at Pain Relief in RA?

MedPage Today

Among rheumatoid arthritis (RA) patients responding to upadacitinib (Rinvoq) or adalimumab, those receiving the former had significantly less residual pain with treatment, according to a post-hoc analysis of phase III trial data.

Read Article
emergency.jpg

Emergency Department Visits by Rheumatoid Patients

Jack Cush, MD

A Canadian population study shows that rheumatoid arthritis (RA) patients have 30% higher emergency department (ED) visit rates for Ambulatory Care Sensitive Conditions (ACSCs) compared to age- and sex-matched population controls.

Read Article
Roche Canada announced that Health Canada has approved obinutuzumab (Gazyva) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy. Following four initial doses in the first year, Gazyva can be administered twice yearly https://t.co/snAVErShjK
Dr. John Cush RheumNow ( View Tweet)
BIOBADASER III Registry shows No Cancer Risk with b/tsDMARDs A large, real-world cohort study of rheumatoid arthritis (RA) finds patients treated with biologic and targeted synthetic DMARDs (b/tsDMARDs) do not have an increased risk of cancer. https://t.co/0oawv88Anq https://t.co/nrsok06gKV

Links:

Dr. John Cush RheumNow ( View Tweet)
Drugs that may cause toxic myopathy, presenting as muscle dysfunction w/ weakness and elevated muscle enzymes and possibly confused w/ idiopathic inflammatory myopathies (IIM) - full read review of mimickers of myositis. https://t.co/1Yn3OXXEH6 https://t.co/HmQiYFSQMU

Links:

Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Anifrolumab in SLE Manzi et al. have published the results of the TULIP-SC trial that showed that weekly subcutaneous (SC) anifrolumab, when given to severe SLE patients, had comparable efficacy and safety to the approved intravenous (IV) anifrolumab. https://t.co/EzaqS5q096
Dr. John Cush RheumNow ( View Tweet)
Are JAK Inhibitors Better at Pain Relief in RA? Among rheumatoid arthritis (RA) patients who responded to upadacitinib (Rinvoq) or adalimumab, those receiving upadacitinib had significantly less residual pain with treatment, according to a post hoc analysis of phase III trial https://t.co/QrbwlxIm3d
Dr. John Cush RheumNow ( View Tweet)
Did you know theres a Subcutaneous (SC) rituximab (Hycela)? Its same RTX but combined w/ hyaluronidase, faster 5-7 minute injection Vs hours for IV RTX. FDA approved 2017 for Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL). Give 1st dose IV, then use SC RTX. https://t.co/piQ2ZhAOyf
Dr. John Cush RheumNow ( View Tweet)
French Retrospective study (2011-22) of 36129 adult psoriasis pts on biologics who recv antibiotics (9366/26% @ baseline, 61% during FU). Abx treatment assoc w/ 12% greater risk biologic D/C (HR 1.12); more for multiple Abx courses (HR 1.29; 95% CI, 1.24-1.35) https://t.co/2Jv5xCibyd
Dr. John Cush RheumNow ( View Tweet)
Emergency Department Visits by Rheumatoid Patients A Canadian population study shows that rheumatoid arthritis (RA) patients have 30% higher emergency department (ED) visit rates for Ambulatory Care Sensitive Conditions (ACSCs) compared to age- and sex-matched population https://t.co/BL8AkXhkFG
Dr. John Cush RheumNow ( View Tweet)
Rheum Survey> 40 yoF RA pt on Prednisone 5 mg/d is at increased risk for ?

Dr. John Cush RheumNow ( View Tweet)

German psoriasis registry PsoBest reports on 595 Rx w/ apremilast (417 APR monotherapy). Compared to Ptx Rx w/ other DMARDs/biologic drugs, APR pts higher age, more comorbidities. Nonserious AEs: ineffectiveness (14%), diarrhea (9%), nausea (7%), HA (6%). https://t.co/TviJmM7Fr9 https://t.co/tY89oHgUgV

Links:

Dr. John Cush RheumNow ( View Tweet)
Diffuse Alveolar Hemorrhage in Rheumatic Disease A retrospective, cross-sectional, single-center study of adult rheumatic disease patients with diffuse alveolar hemorrhage (DAH), demonstrates a high proportion have coexistent pulmonary infection and significant mortality risk. https://t.co/K1fLo5iHpd
Dr. John Cush RheumNow ( View Tweet)
Drugs that may cause toxic myopathy, presenting as muscle dysfunction w/ weakness and elevated muscle enzymes and possibly confused w/ idiopathic inflammatory myopathies (IIM) - full read review of mimickers of myositis. https://t.co/3wdLvkxcAX https://t.co/OqLjv45HXH

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×